U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457151) titled 'Danicopan PMS in Korea' on Feb. 13.
Brief Summary: As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
Study Start Date: March 31
Study Type: OBSERVATIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria
Recruitment Stat...